Human iPSC-Based Modeling Identifies Epigenetic Regulation at the KCNQ1 Locus During Early Islet Development That Contributes to Lower β-Cell Mass
Authors:
Open Access
- 7 April 2026
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 75 (6) , 1038-1049
Abstract
The strongest type 2 diabetes signal in Indigenous Americans from Arizona is in intron 15 of KCNQ1. We previously identified a functional region in this intron that contained four type 2 diabetes–associated single nucleotide polymorphisms (SNPs) (rs2299620, rs2237896, rs2237897, and rs74046911) and demonstrated functionality of this fragment using Indigenous American induced pluripotent stem cell (iPSC)-derived pancreatic islets (SC-islets). In the current study, we used isogenic iPSCs with targeted edits at these four SNPs, and three additional SNPs (rs2237895, rs60808706, and rs234864), to generate SC-islets and study the effect of these variants during different developmental stages. We identify an 11% reduction in stem cell–derived β-cells (SC-β-cells) in SC-islets with the risk alleles, suggesting an effect of these variants on β-cell mass. We further show premature endocrine commitment in cells with the risk allele and lower rate of β-cell commitment during the endocrine progenitor stages, likely due to differences in H19 and INS gene expression dynamics. We also show that the differential expression may be attributable to lower CpG methylation and higher chromatin accessibility in cells with the risk alleles. In summary, the type 2 diabetes SNPs at KCNQ1 affect SC-β-cell generation, and this effect is manifested early during development, likely via an epigenomic effect on gene regulation. Article Highlights: We previously developed an induced pluripotent stem cell–based model to study an intronic region of KCNQ1 that represents the strongest association signal with type 2 diabetes in Indigenous Americans from Arizona. The current study builds on this model by using CRISPR/Cas9-edited isogenic cells that differ only by targeted type 2 diabetes single nucleotide polymorphisms in this intronic region. The effect of KCNQ1 type 2 diabetes single nucleotide polymorphisms on pancreatic β-cell development and the probable mechanism of this effect were previously unknown. The current study shows an effect on INS and H19 gene expression dynamics specifically during the endocrine progenitor stage of pancreatic islet development likely via an epigenomic effect on gene regulation resulting in generation of lower β-like cells. Individuals carrying KCNQ1 risk alleles for type 2 diabetes will likely benefit from therapeutics that increase pancreatic β-cell mass.Keywords
All Related Versions
Funding Information
- Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the National Institutes of Health
This publication has 25 references indexed in Scilit:
- Modelling the effects of human SUR1 R1420H variation on insulin secretory function using isogenic iPSC-derived pancreatic isletsDiabetologia, 2025
- Developments in stem cell-derived islet replacement therapy for treating type 1 diabetesCell Stem Cell, 2023
- Coming full circle: On the origin and evolution of the looping model for enhancer–promoter communicationJournal of Biological Chemistry, 2022
- SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinismDiabetologia, 2021
- CTCF-Mediated Enhancer-Promoter Interaction Is a Critical Regulator of Cell-to-Cell Variation of Gene ExpressionMolecular Cell, 2017
- Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in MexicoNature, 2013
- DNA-binding factors shape the mouse methylome at distal regulatory regionsNature, 2011
- Parental origin of sequence variants associated with complex diseasesNature, 2009
- Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitusNature Genetics, 2008
- CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locusNature, 2000